Iloperidone side effects: orthostatic hypotension and slow titration

Iloperidone, marketed as Fanapt, is an atypical antipsychotic that does not get a lot of attention in clinical conversation but occupies an interesting niche: it is generally well-tolerated for movement-related side effects and has only modest metabolic impact, but it requires the slowest mandatory titration of any oral antipsychotic on the US market. The reason is one specific side effect — orthostatic hypotension, the dizziness that comes from blood pressure dropping when you stand up.

Orthostatic hypotension: why titration matters

Iloperidone is a potent blocker of alpha-1 adrenergic receptors in blood vessels, which normally help maintain blood pressure when you stand up. Block them too quickly and the vessels don't constrict in time — blood pools in the legs, blood pressure drops, and the patient feels lightheaded or faints.

The FDA labelling, available at Drugs@FDA, requires a specific upward titration over about a week to reach the target dose, with explicit instructions on dose increments. Skipping the titration is a recipe for dizziness, falls — particularly dangerous in older patients — and treatment dropout.

Practical strategies during the early weeks:

• Stand up slowly, especially first thing in the morning and after meals
• Sit on the edge of the bed for a moment before standing
• Stay well hydrated
• Avoid alcohol, which compounds the effect
• Be careful with hot showers, which dilate blood vessels and worsen the drop
• Tell your prescriber about other blood pressure medications you take

QT prolongation

Iloperidone modestly prolongs the QT interval — comparable to ziprasidone in some studies. The clinical implications are similar: meaningful for patients with cardiac risk factors, on other QT-prolonging medications, or with electrolyte abnormalities, but minimal for healthy adults. Baseline ECG is reasonable in patients with cardiac history. See QT prolongation and antipsychotics.

Movement effects: a relative strength

One of iloperidone's distinguishing features is a low rate of EPS. Akathisia, parkinsonism, and dystonia rates in pivotal trials were comparable to placebo at standard doses — among the lowest of any antipsychotic. Tardive dyskinesia is theoretically possible with long-term use, as with any dopamine-acting antipsychotic, but appears uncommon.

This makes iloperidone an option worth considering for patients who developed troublesome EPS on other antipsychotics, provided they can tolerate the orthostatic effects.

Weight and metabolic effects

Iloperidone produces modest weight gain — typically less than olanzapine or risperidone, but more than aripiprazole or lurasidone. Average first-year gains are in the 2–4 kg range. Effects on glucose and lipids are modest. Standard metabolic monitoring applies.

Sedation

Moderate. Often less than olanzapine or quetiapine but more than aripiprazole. Many prescribers favour evening dosing.

Prolactin

Iloperidone produces only modest prolactin elevation, similar to or less than asenapine. Symptomatic hyperprolactinemia is uncommon at standard doses.

Other reported effects

• Dry mouth
• Nasal congestion — uncommon but reported, related to alpha blockade
• Tachycardia — usually mild, sometimes reflexive to orthostatic effects
• Fatigue
• Nausea during titration

Drug-metabolism considerations

Iloperidone is metabolised primarily by CYP2D6 and CYP3A4. Patients who are CYP2D6 "poor metabolisers" (a genetic variant present in roughly 7% of people of European descent and a smaller percentage of others) clear the drug more slowly and require lower doses. Strong inhibitors of either enzyme — including some antidepressants (fluoxetine, paroxetine), antifungals, and antibiotics — also raise blood levels and may require dose adjustments. This is one reason your prescriber will want to know everything else you take.

Approved use

Iloperidone is FDA-approved only for the treatment of schizophrenia in adults. It is not approved for bipolar disorder, depression, or other indications.

Boxed warnings

• Increased mortality in elderly patients with dementia-related psychosis (class-wide for antipsychotics)

When to call the prescriber

• Persistent dizziness, especially on standing
• Any fainting episode
• Palpitations, irregular heartbeat, or chest discomfort
• Significant weight gain
• Starting any new medication, including over-the-counter or supplements
• Loss of effect — sometimes a sign of an interaction with a CYP inducer

Switching considerations

If iloperidone is not the right fit, alternatives depend on which side effect was the dealbreaker:

• For continued low EPS preference: quetiapine, lurasidone
• For metabolically lighter options: aripiprazole, ziprasidone, lurasidone
• For broader indications (e.g. bipolar): quetiapine, cariprazine

Why iloperidone is less commonly prescribed

Several practical factors limit iloperidone's use: the mandatory titration creates a logistical hurdle in clinic, the medication is still under brand pricing in some markets making access expensive, and the drug has only the schizophrenia indication. For patients who are willing to do the titration and for whom EPS is a major concern, however, it can be a useful option.

The takeaway

Iloperidone trades a slow start for a relatively gentle long-term ride. The patients who do best on it are those who can tolerate the early orthostatic effects, who value low EPS risk, and whose prescriber walks them carefully through the titration. As with any antipsychotic decision, the choice belongs to the patient and prescriber together — informed by what didn't work before, what side effects are most personally costly, and what realistic alternatives exist.

This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.